CG Oncology (CGON) Institutional Ownership

26.56% of CG Oncology's stock is owned by institutional investors. Learn more on CGON's institutional investor holdings.

Of the 176 institutional investors that purchased CG Oncology's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($7.42M), Foresite Capital Management VI LLC ($2.22M), Price T Rowe Associates Inc. MD ($2.21M), BVF Inc. IL ($1.88M), Marshall Wace LLP ($1.73M), State Street Corp ($1.67M), and Janus Henderson Group PLC ($1.62M).

Institutional investors have bought a total of 20,971,447 shares in the last 24 months. This purchase volume represents approximately $809.21M in transactions.

Of the 61 institutional investors that sold CG Oncology's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Braidwell LP ($1.41M), Orbimed Advisors LLC ($1.08M), Bank of America Corp DE ($988.42K), Pictet Asset Management Holding SA ($951.52K), Millennium Management LLC ($706.79K), CenterBook Partners LP ($326.12K), and UBS Group AG ($305.50K).

Institutional investors have sold a total of 8,111,113 shares in the last 24 months. This volume of shares sold represents approximately $376.83M in transactions.